All the news Showing 10 of 13 articles from: Previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic for HCV News Medical Net / 22 October 2014 Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C Fierce PharmaMarketing / 11 September 2014 European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection Bristol-Myers Squibb / 27 August 2014 Stefan Zeuzem: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed Clinical Care Options (requires registration) / 28 May 2014 New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) Medivir press release / 17 March 2014 European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C European Medicines Agency / 21 February 2014 Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin Healio Hepatology / 12 June 2013 Investigational noninterferon HCV treatment effective across patient groups Internal Medicine News / 30 May 2013 Daclatasvir/asunaprevir effective in difficult-to-treat HCV populations Healio Hepatology / 09 April 2013 Telaprevir shows promise in black patients with genotype 1 HCV Healio / 12 March 2013 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive